BMJ journal deems opioid dependency implant more favourable than tablets
While the opioid epidemic in the USA is well documented, Europe also has an estimated 1.3 million high-risk opioid users.
Read More
Tag: buprenorphine
EU nod for opioid dependence therapy
The European Medicines Agency has issued a marketing authorisation for Orexo and MundiPharma’s Zubsolv (buprenorphine and naloxone) for opioid dependence.
Read More
Appeal court paves way for launch of Sandoz’ Reletrans
Novartis’ generics arm Sandoz is launching its long-acting buprenophine patch Reletrans in the UK following victory in a patent battle with Napp Pharmaceuticals.
Read More
US OKs first implant for opioid addiction
US regulators have approved the first buprenorphine implant to help treat people addicted to opioids, including prescription painkillers and heroin.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
